Quarterly report pursuant to Section 13 or 15(d)

Liquidity (Details Narrative)

v3.19.1
Liquidity (Details Narrative) - USD ($)
3 Months Ended
Jan. 30, 2019
Mar. 31, 2019
Dec. 31, 2018
Accumulated deficit   $ (147,605,049) $ (121,370,240)
Accounts payable   8,962,750 6,345,335
Cash and cash equivalents   $ 89,919,798 $ 41,748,468
Cystic Fibrosis Program Related Investment Agreement [Member]      
Percentage of payment from the upfront payment received   10.00%  
Accounts payable   $ 2,700,000  
Cystic Fibrosis Program Related Investment Agreement [Member] | 2018 CFF Award [Member]      
Milestone received on achievement on clinical trial   12,500,000  
April 2019 [Member] | Cystic Fibrosis Program Related Investment Agreement [Member] | 2018 CFF Award [Member]      
Maximum amount received as development award as funding   25,000,000  
April 2019 [Member] | Cystic Fibrosis Program Related Investment Agreement [Member] | Cystic Fibrosis Foundation [Member]      
Milestone received on achievement on clinical trial   5,000,000  
June 30, 2019 [Member] | Cystic Fibrosis Program Related Investment Agreement [Member] | 2018 CFF Award [Member]      
Expected milestone achievement to be received   5,000,000  
Kaken Pharmaceutical Co., Ltd. [Member]      
Upfront payment received from strategic collaboration   $ 27,000,000  
January 2019 Offering [Member] | Underwritten Public Offering [Member]      
Net proceeds $ 37,700,000